Publications by authors named "Daniela Bartoletti"

Claim this Profile
R
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Francesca Palandri, Massimo Breccia, Camilla Mazzoni, Giuseppe Auteri, Elena Maria Elli, Daniela Bartoletti

Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
Francesca Palandri, Elena M Elli, Giuseppe Auteri, Massimiliano Bonifacio, Giulia Benevolo, Daniela Bartoletti

Blood Cancer J· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study.
Giuseppe Auteri, Simona Paglia, Camilla Mazzoni, Mattia Biondo, Marta Venturi, Daniela Bartoletti

Mediterr J Hematol Infect Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Francesca Palandri, Daniela Bartoletti, Alessandra Iurlo, Massimiliano Bonifacio, Elisabetta Abruzzese

Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
Nicola Vianelli, Giuseppe Auteri, Francesco Buccisano, Valentina Carrai, Erminia Baldacci, Daniela Bartoletti

Ann Hematol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity.
Giuseppe Auteri, Daniela Bartoletti, Christian Di Pietro, Emanuele Sutto, Camilla Mazzoni

Leuk Res· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiological trends of pediatric IBD in Italy: A 10-year analysis of the Italian society of pediatric gastroenterology, hepatology and nutrition registry.
Patrizia Alvisi, Flavio Labriola, Luca Scarallo, Paolo Gandullia, Daniela Knafelz, Daniela Bartoletti

Dig Liver Dis· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Elena Maria Elli, Ambra Di Veroli, Daniela Bartoletti, Alessandra Iurlo, Ida Carmosino

Br J Haematol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies.
Francesca Palandri, Christian Di Pietro, Francesca Ricci, Pier Luigi Tazzari, Vanda Randi, Daniela Bartoletti

Res Pract Thromb Haemost· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.
Giulia Benevolo, Elena M Elli, Daniela Bartoletti, Roberto Latagliata, Mario Tiribelli

Hematol Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Francesca Palandri, Mario Tiribelli, Massimo Breccia, Daniela Bartoletti, Elena M Elli

Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia.
Francesca Palandri, Elena Rossi, Daniela Bartoletti, Antonietta Ferretti, Marco Ruggeri

Blood· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The diagnostic role of Next Generation Sequencing in uncovering isolated splenomegaly: A case report.
Giuseppe Auteri, Daniela Bartoletti, Clara Bertuzzi, Francesco Bacci, Valeria Tonini

Hematol Rep· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Nicola Polverelli, Elena M Elli, Elisabetta Abruzzese, Giuseppe A Palumbo, Giulia Benevolo, Daniela Bartoletti

Br J Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients' satisfaction.
Francesca Palandri, Daniela Bartoletti, Stefania Giaquinta, Federica D'Ambrosio, Giuseppe Auteri

Br J Haematol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
Francesca Palandri, Giuseppe Alberto Palumbo, Elena Maria Elli, Nicola Polverelli, Giulia Benevolo, Daniela Bartoletti

Blood Cancer J· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
Francesca Palandri, Massimo Breccia, Mario Tiribelli, Massimiliano Bonifacio, Giulia Benevolo, Daniela Bartoletti

Hematol Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis.
Martina Barone, Lucia Catani, Francesca Ricci, Marco Romano, Dorian Forte, Daniela Bartoletti

Oncoimmunology· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-Specific Derangement of Circulating Endocannabinoids and -Acylethanolamines in Myeloproliferative Neoplasms.
Dorian Forte, Flaminia Fanelli, Marco Mezzullo, Martina Barone, Giulia Corradi, Daniela Bartoletti

Int J Mol Sci· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Francesca Palandri, Massimo Breccia, Massimiliano Bonifacio, Nicola Polverelli, Elena M Elli, Daniela Bartoletti

Cancer· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years.
Francesca Palandri, Cristina Santoro, Monica Carpenedo, Silvia Cantoni, Wilma Barcellini, Daniela Bartoletti

Thromb Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.
Francesca Palandri, Giuseppe A Palumbo, Elisabetta Abruzzese, Alessandra Iurlo, Nicola Polverelli, Daniela Bartoletti

Hematol Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis.
Martina Barone, Francesca Ricci, Daria Sollazzo, Emanuela Ottaviani, Marco Romano, Daniela Bartoletti

Br J Haematol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.
Massimo Breccia, Daniela Bartoletti, Massimiliano Bonifacio, Giuseppe A Palumbo, Nicola Polverelli

Ann Hematol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.
Francesca Palandri, Giuseppe A Palumbo, Alessandra Iurlo, Nicola Polverelli, Giulia Benevolo, Daniela Bartoletti

Semin Hematol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis